Melarsomine dihydrochloride (Immiticide®, Merial) is the only approved adulticidal
drug for the treatment of canine
heartworm disease (HWD). However, in cases where arsenical
therapy is not possible or is contraindicated, a monthly heartworm preventive along with
doxycycline for a 4-week period, which targets the bacterial endosymbiont Wolbachia, might be considered. There are published reports on the efficacy of
ivermectin and
doxycycline in both experimentally and naturally infected dogs, but no data on the use of other macrocyclic
lactones (MLs) with a similar treatment regime. Preliminary results of studies in dogs show that a topical formulation of
moxidectin, the only ML currently registered as a microfilaricide, is also adulticidal when combined with
doxycycline. It is not yet known if the efficacy of these combination
therapies is due to pharmacokinetic synergism. A recent study showed that serum levels of
doxycycline in dogs treated with the combination protocol were not statistically different compared to dogs treated with
doxycycline alone. However, lungs from dogs treated with the combination
therapy showed a marked reduction in T regulatory cells, indicating that treatment efficacy may be due to a heightened immune response against the parasite. Further studies are necessary to evaluate the long-term clinical outcome of combination protocols and to establish the most efficient treatment for HWD in dogs.